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Synopsis  
There is a wide inter-individual variation in PARP activity, which may have implications for 
health. We investigated if the variation (i) is due to polymorphisms in the PARP-1 gene or 
PARP-1 protein expression and (ii) affects patients’ response to anticancer treatment. 
We studied 56 healthy volunteers (HV) and 118 cancer patients (CP), with supporting in vivo 
experiments.  
PARP activity ranged between 10–2600 pmol PAR/106 cells and expression between 0.02–
1.55 ng PARP-1/µg protein. PARP-1 expression correlated with activity in HV (R2=0.19, 
P=0.003) and CP (R2=0.06, P=0.01). A short CA repeat in the promoter was significantly 
associated with increased cancer risk (OR, 5.22; 95% CI, 1.79–15.24). PARP activity was 
higher in men than women (P=0.04) in the HV. Male mice also had higher PARP activity 
than females or castrated males. Estrogen supplementation activated PARP in PBMCs from 
female mice (P=0.003) but inhibited PARP in their livers by 80%.  
PARP activity and expression were not dependent on the investigated polymorphisms but 
there was a modest correlation of PARP activity with expression. Studies in the HV revealed 
sex differences in PARP activity, confirmed in mice and associated with sex hormones. 
Toxic response to treatment was not associated with PARP activity and/or expression. 
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Introduction  
 
Poly(ADP-ribose) polymerase-1 (PARP-1) is involved in DNA repair, genomic stability, 
transcription control, cell death and proliferation (reviewed in [1, 2]). Binding of PARP-1 at 
DNA breaks activates the enzyme to cleave NAD+ and create long homopolymers of ADP-
ribose attached to both PARP-1 itself and histone tails at the vicinity of the break, thereby 
“flagging” the damage to the repair machinery. PARP-1 knockout mice, and the cells derived 
from them, are hyper-sensitive to DNA methylating agents, topoisomerase I poisons and 
ionising radiation. These agents are used in the treatment of cancer and PARP inhibitors 
increase their anticancer activity (reviewed in [1, 2]). Paradoxically, PARP activity can also 
promote cell death in non-replicating normal cells that are not so dependent on rapid DNA 
repair. In such cells and tissues a burst in reactive oxygen species formation following 
ischemia-reperfusion injury, infection and inflammation leads to DNA breaks that activate 
PARP-1 resulting in rapid and catastrophic NAD+ and ATP depletion and subsequent cell 
death (reviewed in [3]). Clearly, PARP activity has implications in human health and disease 
and response to anticancer therapy. Large inter-individual differences in PARP activity in 
peripheral blood mononuclear cells (PBMCs) have been reported in both healthy volunteers 
and cancer patients [4-7].  High PARP activity may promote DNA repair and genomic 
stability in normal cells as well as cancer cells thus can lead to resistance to DNA-damaging 
anticancer treatment. However, low PARP activity may lead to reduced pro-inflammatory 
mediators, tissue damage, necrosis and reperfusion injury.  
Little is known about the potential underlying mechanisms responsible for the variation in 
PARP-1 activity and expression. There are at least 60 reported single nucleotide 
polymorphisms (SNPs) in the PARP-1 sequence (http://snp500cancer.nci.nih.gov). One of 
these polymorphisms in the promoter region is a microsatellite polymorphic DNA fragment, 
consisting of a variable number of CA repeats [8] that may facilitate transcription from the 
promoter via the formation of DNA quadruplex structures [9]. Furthermore, the CA 
microsatellite is located close to the binding site of the transcription factor Yin Yang 1 (YY1), 
and this may also contribute to the regulation of transcription [10, 11]. The common T2444C  
SNP (at a frequency of 5-33%), resulting in an amino acid substitution, Val762Ala, in the 
PARP-1 catalytic domain, has been reported to reduce PARP-1 catalytic activity by 30-40% 
and to be associated with various cancers [4, 12-15]. 
Numerous studies suggest a correlation between PARP activity and age. A positive 
correlation between specific PARP activity and mean maximal life span in 13 mammalian 
species as well as a decrease in PARP activity with age in humans and rats was previously 
reported [16]. In contrast, enhancement of PARP activity was reported in brains of old adult 
animals compared with young controls [17] and in lymphoblastoid cell lines derived from 
centenarians [7].  
Patients vary in their toxic and therapeutic response to treatment due to several different 
factors and pharmacogenetics may be used to predict toxicity and response allowing more 
tailored drug treatment. Recent clinical trials with PARP inhibitors indicate that suppression 
of PARP-1 activity can have a profound effect on chemotherapy induced toxicity [18] as well 
as the efficacy of chemotherapy [19].  An understanding of the genetic determinants of 
PARP-1 activity and its relation to patients’ response was investigated in this study. 
Our aim was to further evaluate the inter-individual differences in PARP activity and 
determine the underlying mechanisms responsible for the variation in terms of PARP-1 
protein expression, polymorphisms in the PARP-1 gene and demographic factors such as 
age and sex. We investigated the underlying mechanisms by measuring PARP-1 
polymorphisms, expression and activity in PBMCs from 118 cancer patients and 56 healthy 
volunteers, with supporting in vivo studies. We also studied if PARP-1 activity contributes to 
patients’ response to treatment in terms of toxicity and if particular types of malignancy are 
associated with higher or lower PARP activity. 
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Materials and Methods 
Chemicals  
β-estradiol 17-valerate and all routine chemicals and tissue culture reagents were supplied 
by Sigma (Dorset, UK) unless stated otherwise. AG014699 was a kind gift from Dr Zdenek 
Hostomsky (Pfizer Oncology, La Jolla, USA).  
Cell line  
Chronic myelogenous leukaemia K-562 cells obtained from ATCC (CCL-243, Manassas VA, 
USA) were cultured in RPMI-1640 medium with 10% fetal bovine serum and 1% antibiotic-
antimycotic at 37ºC in an atmosphere of 5% CO2 in air. Cells were confirmed Mycoplasma 
negative by regular testing (Mycoalert; Cambrex, Charles City, IA, USA).  
Hormonal manipulation in mice 
 
The animal study was conducted in accordance with national law and institutional guidelines 
under a protocol approved by local Ethics Committee. CD-1 mice, 8-10 weeks of age 
(Charles River Laboratories, Wilmington, MA, USA), were treated as follows: male untreated 
controls (n = 9), castrated untreated males (n = 9), castrated males  treated with 4 mg β-
estradiol 17-valerate per mouse dissolved in corn oil (n = 15) by a single intramuscular (IM) 
injection on the day of castration, untreated females (n = 9) and females (n = 15) treated with 
β-estradiol 17-valerate as above. Animals were killed 6 days later and blood from controls (n 
= 3) and treated animals (n = 5) was pooled prior to collection of PBMCs. Livers from control 
female mice (n = 3) and from estradiol treated female mice (n = 3) were also collected for 
analysis and stored in -80°C. 
Human subjects  
The research protocol for the PARP clinical study was approved by the local Ethics 
Committee. The study included cancer patients (CP) newly diagnosed with solid tumours 
who were referred to Northern Centre for Cancer Treatment (NCCT) between February 2007 
– December 2008 and healthy volunteers (HV). Subjects supplied a blood sample (10-20 ml) 
and data including date of birth, sex, ethnicity, weight, type of diagnosed disease, stage and 
grade, treatment, co-medication, co-morbidities and response to treatment (CP) or data on 
their sex, age, weight and ethnicity (HV). The demographic characteristics of the HV and CP 
in this study are listed in Table 1.  
Assessment of toxicity in patients undergoing anticancer treatment 
Toxicity after the first cycle of chemotherapy or the first course of radiotherapy or concurrent 
radiotherapy and chemotherapy was graded according to The National Cancer Institute 
Common Terminology Criteria for Adverse Events version 3.0 (CTCAE).  Assessment of 
neutropenia or other myelotoxicity was based upon blood analysis before second cycle of 
treatment. The analysis of toxicity was based on a comparison of the rates of grade 3 and 
greater toxicity.  
Genotyping 
 DNA was isolated directly from blood using Blood Mini Kit (Qiagen, UK) according to the 
manufacturer's instructions and genotyped for T2444C SNP by pyrosequencing using the 
PSQ96 system (Pyrosequencing, Uppsala, Sweden) and for CA microsatellite capillary using 
the electrophoresis system CEQ8000 (Beckman Coulter, UK) as described previously [20].  
Western blot analysis  
Briefly, the cell pellet was lysed in 100 µl of Laemmli buffer with 1x Halt protease inhibitor 
cocktail (Thermo Fisher Scientific) sonicated on ice for 10 s  and heated in loading dye 
containing β-mercaptoethanol and bromophenol blue at 95°C for 5  min. Lysates (30 µg of 
protein per lane) were run on Tris-HCl 5-20% polyacrylamide gels (Bio-Rad, Hercules, CA) 
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along with purified recombinant PARP-1 immunoblotting standard  (0-40 ng: Enzo Life 
Sciences, UK) at 100 V for 2 h and transferred for 1 h at 4°C into a nitrocellulose membrane 
(Hybond-C, Amersham, UK) (Criterion electrophoresis and blotting apparatus, Bio-Rad). 
After blocking for 1 h in PBS-MT (PBS+ 5% non-fat powdered dried milk and 0.5% Tween 
20) the membrane was incubated overnight at 4°C wit h an anti-PARP-1 C2-10 primary 
antibody (1:2000 in PBS-MT Trevigen, Gaithersburg, MD) washed 3x in PBS-T (PBS+ 0.5% 
Tween 20), and then incubated with the HRP-linked secondary goat anti-mouse antibody 
(1:1000 in PBS-MT Dako)  washed again for 1 h in PBS-T and dried. The protein was 
visualised with ECL plus detection kit (Amersham, Little Chalford, UK) using the 
manufacturer’s protocol followed by chemiluminescence detection using a Fuji LAS3000 with 
imaging software (Fuji LAS Image version 1.1, Raytek). PARP-1 expression was quantified 
by reference to the recombinant PARP-1 standard curve. This assay was validated to GCLP 
standard for evaluation of patient samples (E. Mulligan and T. Zaremba, unpublished data). 
Validation studies showed that loading the lysate in duplicate with protein determination 
gave more reliable data than use of a loading control such as GAPDH and β-actin. 
Additionally, using a purified PARP-1 standard and a quality control sample (protein extract 
from K562 cells) assured the quality of transfer and allowed the most precise protein 
quantification.  
PARP activity assay 
Total stimulatable PARP activity was measured by modification of a previously described 
method [6] validated to GCLP standard and used as a pharmacodynamic endpoint for 
clinical trials [18]. This assay measures PARP activity that has been maximally stimulated by 
a double-stranded ologonucleotide in the presence of excess NAD+, thereby eliminating 
error due to variable activation of the enzyme by DNA damage accidentally introduced 
during processing. Quality control (QC) samples of L1210 cells were included in each assay. 
As part of the validation of this assay the day-to-day variation between samples from the 
same individual was measured in independent experiments. In 8 individual HV the mean 
maximum variation in PARP activity, measured on 3 different days, was 1.5 ± 0.2-fold. PARP 
activity was measured in triplicate samples of 104 digitonin permeabilised cells in a reaction 
mixture containing 350 µmol/L NAD+ and 10 µg/mL oligonucleotide (CGGAATTCCG) 
(Europrim, Invitrogen, UK) in a reaction buffer of 100 mmol/L Tris-HCl, 120 mmol/L MgCl2 
(pH 7.8) in a final volume of 100 µL for 6 min at 26°C. After blotting onto a nitrocellulose 
membrane (Hybond-N, Amersham, UK), the poly(ADP-ribose) was detected following 
incubation with the primary anti-PAR 10H antibody 1:1000 then HRP-conjugated goat anti-
mouse secondary antibody (1:1000 Dako, Ely, UK) and finally ECL reaction and 
chemiluminesence detection as described above. Results were expressed relative to the 
number of cells loaded by reference to a poly(ADP-ribose) standard curve (0-25 pmol: Enzo 
Life Sciences). 
Mouse liver samples were thawed and the wet weight recorded prior to homogenisation in 3 
volumes ice-cold isotonic buffer (Ultra-Turrax T25, Janke and Kunkel, Staufen, Germany.  
The homogenate was diluted with isotonic buffer to yield a final dilution of 1 in 2000. The 
protein content was measured by the colorimetric Pierce protein assay (Thermo Scientific) 
prior to assay of PARP activity as described above.  
Statistical analysis  
Each sample was analyzed in triplicate (PARP activity) or in duplicate (PARP-1 expression) 
and mean presented. The normality of the data distribution was tested by Shapiro-Wilk and 
D'Agostino & Pearson tests (GraphPad, La Jolla, CA).  The distribution of PARP activity and 
expression was highly skewed and so a base-10 logarithmic transformation was applied in 
order to obtain a more Gaussian like distribution.  Mean log transformed PARP activity, and 
expression, was compared between sexes and between HV and CP using the Student’s t-
test. Analysis of covariance (ANCOVA) and linear regression were used to determine 
associations between activity and expression, and between activity, expression and age, 
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weight and sex.  The χ2 test and Freeman-Halton extension of the Fisher’s exact test were 
used for analysis of genotype frequencies. The level of significance was set at 0.05. 
RESULTS  
PARP-1 gene polymorphisms   
T2444C SNP (Val762Ala) in the catalytic domain 
The T2444C SNP (rs1136410), resulting in an amino acid substitution, Val762Ala, in the 
PARP-1 catalytic domain is reported to lead to reduced PARP-1 catalytic activity. The 
genotype frequencies are given in Table 2. There was no evidence that the distribution was 
not in Hardy-Weinberg equilibrium in HV and CP (P = 0.88 and P = 0.31, respectively). The 
variant (minor) allele frequency (MAF) for both groups was 14% and was within reported 
range for studied populations (5 - 33%) [21-23]. There was no difference in genotype 
distribution between HV and CP (P = 0.9). Neither the T/C nor the C/C genotypes were 
associated with an increased risk of cancer when compared with T/T  (OR, 1.06; 95% CI, 
0.50 – 2.20 and 0.48; 95% CI, 0.03 – 7.81, respectively).  
(CA)n  microsatellite instability in PARP-1 promoter region 
 
It has been proposed that a long CA polymorphism in the promoter region of the PARP-1 
gene may result in increased PARP-1 expression. We therefore investigated the length of 
these microsatellite repeats in all subjects’ genomic DNA samples. Analysis of the allele 
frequencies in HV and CP revealed the presence of the two most common alleles namely 
(CA)11 and (CA)15, which formed the three most common genotypes: HV, (CA)11/(CA)11 
(61%),
 
(CA)11/(CA)15 (16%) and (CA)15/(CA)15 (9%) and CP, (CA)11/(CA)11 (78%), 
(CA)11/(CA)15 (14%) and (CA)15/ (CA)15 (3%). As previously established [24] we grouped the 
CA microsatellite into two alleles: S (Short) comprising (CA)11 – (CA)12 and L (Long) 
comprising (CA)13 – (CA)20. Genotype frequencies given by this biallelic approach are 
presented in Table 2. There was a statistically significant difference in the genotype 
distribution between cancer patients and control subjects (P = 0.003); CP had a higher 
frequency of the SS genotype compared to HV (80% versus 59%). The SS genotype was 
significantly associated with an increased risk of cancer (OR, 5.22; 95% CI, 1.79–15.24) 
using LL as the reference group. 
PARP-1 expression 
 
We found that PARP-1 protein expression (see for example, Supplementary Figure 1S), 
successfully analyzed in 44 HV subjects, showed a large variation between the lowest and 
the highest expression in subjects (CV = 95%); range 0.02 - 0.78 ng PARP-1/µg protein with 
a mean value of 0.21 ng/µg and a median value of 0.12 ng/µg.  Significant variation in 
PARP-1 expression was also observed in CP (0.03 - 1.55 ng/µg, CV = 104%) with a mean 
value of 0.23 ng/µg and median value of 0.16 ng/µg. We did not observe any statistically 
significant difference in expression between HV and CP (P = 0.18, Fig. 1A) or men and 
women either in HV or in CP (P = 0.1 and P = 0.13, respectively, Fig. 1B).  
PARP activity  
There was a large variation in PARP activity (see for example, Supplementary Fig. 2S) in 
HV (n = 56) with values ranging between 10 and 2190 pmol PAR/106 PBMCs (CV = 120%), 
mean value of 508.6 pmol/106 cells and median value of 260 pmol PAR/106 cells. Similarly, 
we observed large variation in PARP activity between CP (n = 118, CV = 137%) ranging 
between 10-2600 pmol/106 cells with mean value of 357.7 pmol/106 cells and median value 
of 160 pmol PAR/106 cells. There was no statistically significant difference in PARP activity 
between HV and CP (P = 0.45, Fig. 2A). However, we observed a difference in PARP 
activity in HV between men and women (P = 0.04, Fig. 2B).  
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Dependence of PARP activity on PARP-1 genotype and PARP-1 protein expression 
 
We found no association between the T2444C genotype and PARP activity (T/T vs. T/C, P = 
0.24 and P = 0.34, for HV and CP respectively, Fig. 3A). It was not possible to perform any 
statistical analysis on the C/C genotype as we only had one sample with the C/C variant 
genotype in each group of subjects. We found no association between the (CA)n 
microsatellite polymorphism and PARP-1 expression  (Fig. 3B). 
 We hypothesised that PARP activity would be dependent on the level of PARP-1 protein 
expression. There was a statistically significant but modest positive correlation between the 
level of PARP-1 protein expression and PARP activity in the HV (n = 44, R2 = 0.19, P = 
0.003, Fig. 4A).  A positive but even weaker correlation was also found between PARP-1 
expression and activity in CP (n = 118, R2 = 0.06, P = 0.01, Fig. 4B).  
 
Demographic effects on PARP expression and activity 
In contrast to PARP-1 expression, comparison of gender differences in PARP activity in HV 
(Fig. 2B) revealed that men had significantly higher activity than women (P = 0.04).  The 
median PARP activity in PBMCs from men was 550 pmol PAR/106 cells (range 10 – 1700 
pmol PAR/106 cells) with CV = 83.7%. The median value for women was 130 pmol PAR/106 
cells (range 10 – 21900 pmol PAR/106 cells) with CV = 147.4%. The gender difference 
persisted after allowing for differences in PARP-1 expression (ANCOVA).  On average, 
males had a 1.9 fold (95% CI, 1.2 - 2.8) higher level of PARP activity compared to females 
after adjusting for differences in PARP-1 expression (P = 0.006).  
 
Following the previous reports showing that the age of the subject may affect PARP activity 
we investigated the relationship between the age and weight of subjects and PARP-1 
expression and activity.  PARP activity was negatively correlated with age (P = 0.02) in CP 
but a similar association was not seen in HV (P = 0.9) (Fig. 5A). On average, for each 10 
year increase in age, PARP activity in CP reduced by 19% (95% CI, 4 - 31%).  PARP activity 
was not associated with weight in HV or CP (Supplementary Figure 3S).  We observed no 
association between PARP-1 expression and age (Fig. 5B), however PARP-1 expression 
was found to be significantly positively correlated with weight in CP (P = 0.01).  On average, 
for each 10 kg increase in weight, PARP-1 expression increased by 13% (95% CI, 3 - 
23%).This association was not found in HV (Supplementary Figure 4S).  
In vivo studies of PARP activity in mice treated with estrogen  
To investigate the role of estrogen in the regulation of PARP activity we performed hormonal 
manipulation in mice. PARP activity in PBMCs was approximately 40% higher in male mice 
(920 ± 20 pmol PAR/106 cells) compared with female mice (570 ± 70 pmol PAR/106 cells,    
P = 0.004) (Fig. 6A). Castration led to a significant decrease in PARP activity (710 ± 38 
pmol PAR/106 cells) (P = 0.0005). Estrogen supplementation of castrated male mice did not 
change the level of PARP activity. Paradoxically, estrogen supplementation in female mice 
caused a significant increase in PARP activity in PBMCs (880 ± 30 pmol PAR/106 cells,       
P = 0.003) bringing it to the level similar to that in control untreated male mice. In marked 
contrast, PARP activity was about 80% reduced in liver homogenates from estrogen treated 
female mice (0.15 ± 0.05 pmol PAR/mg protein) compared with untreated female mice (0.9 ± 
0.42 pmol PAR/mg protein) (Fig. 6B).  
PARP activity and patients’ response to treatment 
We evaluated patients’ response to anticancer treatment in terms of toxicity in 44 patients. 
We have only chosen patients whose treatment was “PARP relevant” that is, those agents 
known to cause more cytotoxicity and toxicity in PARP null or inhibited cells or mice, 
respectively. We studied patients treated with temozolomide and dacarbazine (alkylating 
agents), radiotherapy only (ionizing radiation), and radiotherapy in combination with the 
following chemotherapeutic agents: temozolomide, cisplatin (radiosenstizer, cross-linking 
agent), capecitabine (antimetabolite).  Among the 44 patients studied 15 (34%) developed 
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toxicity grade 3 or greater (Table 3). The remaining 29 patients (66%) tolerated treatment 
well with no toxicity or toxicity less than grade 3 (Supplementary Table 3S). Patients 
treated with radiotherapy in combination with cisplatin were far more likely to experience 
high grade 3 or greater toxicity, OR 13.2; 95% CI, 2.9 - 58.9.  However, even after adjusting 
for exposure to cisplatin, there was no evidence of a relationship between high grade toxicity 
and PARP activity or PARP-1 expression (P = 0.5 and P = 0.74, respectively), nor was there 
evidence of a relationship between high grade toxicity and T2444C genotype (P = 0.22). 
 
DISCUSSION 
Since PARP activity may have profound implications for health and studies reveal a wide 
inter-individual variation in PARP activity the overall goal of this study was to determine the 
mechanisms underlying this inter-individual variation. To this end we measured 
polymorphisms in the PARP-1 gene that could affect its expression and activity, PARP-1 
protein levels and demographic factors in relation to PARP activity in PBMCs from human 
subjects.  
Our study revealed a large variation (CV = 120% and 137% for HV and CP, respectively) in 
PARP activity between individuals. Inter-individual variation in PARP-1 expression was much 
lower (CV = 95% and 104% for HV and CP, respectively). Although there was a positive 
correlation between PARP-1 expression and activity in the HV and CP, supporting the 
hypothesis that PARP activity reflects its abundance, the correlation was not as strong as 
expected with only about 20% (HV) and <10% (CP) of the variation in activity is explained by 
variation in expression. 
In the 174 individuals we studied we did not find that the T2444C SNP in the active site 
affected PARP activity, which is similar to observations made by Cottet et al. [21] in 95 
individuals. However, another study [4] of 354 individuals as well as in vitro studies [13, 15] 
using purified PARP enzyme did report a decrease in PARP activity associated with the 
variant allele. Whether the difference is only detectable in large studies or whether the 
method used to determine PARP activity (H2O2 stimulation [4] or in vitro analysis [13, 15]) is 
responsible for the different findings is not possible to say at this time, but it is clearly worthy 
of further investigation using a standardised protocol. Similarly, the observed inter-individual 
variation in PARP-1 expression was not affected by the polymorphisms in the promoter 
region of PARP-1 gene; the two allelic approach, grouping all identified alleles into short (S) 
and (L) and further correlation analysis with PARP-1 expression did not show any 
association between the level of PARP-1 protein and the length of microsatellite.  
The lack of correlation between PARP activity and genotype, with only a limited influence of 
PARP-1 expression, suggested that other factors may play a role in the regulation of PARP 
activity, such as demographics. We confirmed previously reported [16] negative correlation 
between PARP activity and age. This was only seen in CP where there was a 66-year 
difference between the youngest and oldest subject (22-88 years), although there was 
substantial overlap in the age distribution in the HV compared to the CP the age distribution 
was narrower (41 years; 18-69) and hence a trend more difficult to determine. For the first 
time we showed that PARP activity was not associated with weight.  
Our most striking and novel observation was a statistically significant difference (P = 0.04) in 
PARP activity between men and women (HV). We found that younger women (<45 years, an 
age chosen based on epidemiological studies: www.nhs.uk/Conditions/Menopause) 
generally had lower activity (mean 414.1 pmol PAR/106 cells, 95% CI, 133.1 - 695.1) than 
older women, who had intermediate activity (mean 427.5 pmol PAR/106 cells, 95% CI, 73.6 - 
781.3) between young women and men (mean 688.8 pmol PAR/106 cells, 95% CI, 419.1 – 
958.4) but the difference was not statistically significant. The gender differences found in HV 
were not found in CP (P = 0.242), possibly because they were largely in the over 45 year-old 
group (94% of CP women). There are no previous reports of gender differences in PARP 
activity in humans although sexual dimorphisms in PARP-1 activity have been reported in 
animal models [25, 26]. Our finding in humans and published data in animals suggesting 
hormonal regulation of PARP activity led us to conduct further investigations of hormone 
effects in mice. As with the human subjects PARP activity in male mice was significantly 
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higher than in females. PARP activity in castrated males was significantly reduced compared 
to intact males and similar to that in females. However, estrogen supplementation failed to 
reduce PARP activity further in castrated males. Thus, it seems more likely that gender 
differences in PARP activity in PBMCs are due to androgen-mediated stimulation rather than 
estrogen-mediated inhibition of PARP activity. Consistent with this hypothesis is the 
observation that PAR formation was approx. 2-fold higher in brain tissue from male mice 
than females in a stroke model [27] and that PARP-1 mediated damage following cerebral 
ischaemia was significantly reduced in castrated mice [28]. However, estrogen 
supplementation profoundly reduced PARP activity in the liver, consistent with the observed 
estrogen-mediated PARP inhibition in the livers but not PBMCs of male mice treated with 
LPS [25]. This differential effect of estrogen on different tissues warrants further investigation 
as it may be relevant to diseases where PARP-1 activation has pathological effects (e.g. 
diabetes, [29]) and where there are sex differences in incidence or outcome (e.g. primary 
liver cancer, [30]). 
One of the aims of this study was to correlate PARP activity with patients’ response to 
treatment in terms of toxicity. The work presented here is the first study of PARP activity in 
relation to toxicity in patients receiving chemo- or radiotherapy. Patients vary in their 
response to chemo- and/or radiotherapy and the underlying mechanism comprise numerous 
different factors including the patient’s genetic profile (pharmacogenetics) and age. Recent 
studies demonstrate a potentiation of both anticancer activity and toxicity when cytotoxics 
are combined with PARP inhibitors [18, 19, 31]. These data suggest that PARP activity may 
not only have an impact on therapeutic response but also the toxic response to chemo- or 
radiotherapy. We did not observe any significant difference in PARP activity between 
patients who suffered substantial toxicity (grade 3 and above) and those with no symptoms 
of toxicity. We confirmed the high levels of toxicity with cisplatin-radiotherapy combinations 
[32], but again the patients’ PARP activity did not appear to influence the toxic response. 
Additionally, we observed that 40% of men but only 21% of women experienced high grade 
toxicity. In contrast to our findings, several clinical trials have reported greater toxicity in 
women [33, 34].   
Analysis of the CA repeat polymorphism and the two allelic approach, where alleles were 
grouped into short (S) and (L) revealed that the SS genotype was associated with increased 
risk of cancer (OR, 5.22; 95% CI, 1.79–15.24) compared with LL genotype, which was 
underrepresented in CP. To the best of our knowledge this is the first time that the length of 
the CA microsatellite has been linked with cancer risk. Since we did not find an associated 
effect on PARP-1 expression or activity the functional consequences of short CA repeat that 
could explain the increased cancer risk remains to be determined. 
In summary, in this study we tried to find a possible explanation for the observed large inter-
individual variation in PARP activity and if it had an impact on patients’ toxicity, with a view to 
progression towards individualised therapy. We did not find any strong evidence that genetic 
factors play a role in determining PARP activity. The lack of any association between PARP 
activity and genotype or sex in CP may indicate additional factors (e.g., stress hormones, 
interaction with other proteins and posttranslational modifications) may play a role in PARP 
activation. However, we did not find any association between PARP activity and patients’ 
response to treatment.  
An unexpected observation was that PARP activity shows only a modest dependence on 
PARP-1 protein expression, indicating that endogenous or exogenous factors play a major 
role in regulating PARP activity. Importantly, we show for the first time gender difference in 
PARP activity in the normal human population. Given that PARP activity can have 
implications for human health, further investigations of the role of hormones on PARP 
activity and the tissue specificity of the effect are warranted.  
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Tables  
Table 1 Baseline characteristics of eligible group of participants. For age, and weight mean 
values ± SD are given, with range in brackets and median value in square brackets (age 
only). Information on age was available for n = 156 and for weight n = 139. 
 
Variable HV CP 
Total  56 118 
Sex 
 
Men 20 (36%) 65 (55%) 
Women 36 (64%) 53 (45%) 
Ethnic origin 
 
Caucasian 53 (95%) 118 (100%) 
African 1   (2%) 
 
Asian 2   (3%) 
Age (years) 36 ± 13 (18-69) [30] 63 ± 13 (21-88) [64] 
Men 31 ± 12 [26] 62 ± 14 [65] 
Women 39 ± 13 [40] 61 ± 12 [60] 
Body weight (kg) 68 ± 11 (48-95) 74 ± 17 (42-120) 
Men 75 ± 6 81± 17 
Women 64 ± 11 67  ± 14 
 
Table 2 Distribution of PARP-1 genotypes. 
 
Polymorphisms Major homozygote 
T/T, n (%) 
Heterozygote 
T/C, n (%) 
Minor Homozygote 
C/C, n (%) 
P=0.9 
T2444C 
(Val762Ala) 
 
HV 41 (73) 14 (25) 1 (2) 
CP 86 (73) 31 (26) 1 (1) 
OR (95% CI) Ref. 1.06 (0.50-2.20) 0.48 (0.03-7.81) 
 
(CA)n SS, n (%) SL, n (%) LL, n (%) 
P=0.003 HV 33 (59) 12 (21) 11 (20) CP 94 (80) 18 (15) 6 (5) 
OR (95% CI) 5.22 (1.79-15.24) 2.75 (0.80-9.45) Ref. 
 
*For  active site T2444C SNP C/C is a variant/variant. 
#
 Promoter polymorphism SS – short alleles (CA)11-12/(CA)11-12, SL – short/long alleles (CA)11-
12/(CA)13-20, LL - long/long alleles (CA)13-20/(CA)13-20. 
PARP expression and activity 
 
14 
 
Table 3 High grade toxicity (grade ≥ 3) observed in patients treated with PARP relevant 
treatment (n = 15). PARP activity expressed as pmol PAR/106 PBMCs. PARP-1 expression 
presented in ng/µg total protein. Genotype for catalytic domain SNP (T2444C) is also given. 
Abbreviations: TMZ, temozolomide; CIS, cisplatin; CAP, capecitabine. 
 
Patient 
No. Treatment Adverse Event grade ≥ 3 
PARP 
activity 
PARP 
expression 
T2444C 
SNP 
1015 TMZ severe allergic reaction 860 0.36 T/T 
1119 radiation 55 Gy mucositis 140 0.14 T/T 
1123 tamoxifen + radiation 45 Gy erythema, skin reaction 390 0.12 T/C 
1148 CIS + radiation 63 Gy vomiting, nausea 580 0.3 T/T 
1135 CIS + radiation 63 Gy mucositits, skin reaction 140 0.19 T/T 
1133 CIS + radiation 63 Gy mucositis, dysphagia 830 0.18 T/T 
1066 CIS + radiation 63 Gy mucositis, dysphagia, diarrhoea, renal failure 130 0.08 T/T 
1073 CIS + radiation 55 Gy lethargy, dysphagia, mucositis 300 0.1 T/C 
1055 CIS + radiation 63 Gy erythema, mucositis 150 0.63 T/C 
1033 CIS + radiation 63 Gy mucositis, skin reaction toward 
radiotherapy 080 0.12 T/C 
1034 CIS + radiation 63 Gy mucositis, dysphagia 60 0.17 T/T 
1009 CIS + radiation 63 Gy vomiting, diarrhoea 40 0.43 T/T 
1001 CIS + radiation 63 Gy mucositis, erythema, lymphopenia 130 0.19 T/T 
1087 CIS + radiation 63 Gy mucositis 170 0.08 T/C 
1004 CAP + radiation 25 Gy nausea 90 0.16 T/T 
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Legend to figures  
 
Fig. 1 A PARP-1 expression (log10 transformation) in PBMCs from healthy volunteers (HV, n 
= 44) and cancer patients (CP, n = 118). Each data point, a single individual; horizontal line, 
mean for the respective groups of samples. The difference between the two groups is not 
statistically significant (P = 0.18 by Student’s t-test).  
B PARP-1 expression (log10 transformation) in HV men (n = 12), HV women (n = 32) CP 
men (n = 65) and CP women (n = 53). Each data point, a single individual; horizontal line, 
mean for the respective groups of samples. The difference between the two groups is not 
statistically significant (P = 0.1 and P = 0.13 for HV and CP, respectively). 
 
Fig. 2 A PARP activity (log10 transformation) in PBMCs from healthy volunteers (HV, n = 56) 
and cancer patients (CP, n = 118). Each data point, a single individual; horizontal line, mean 
for the respective groups of samples. The difference between the two groups is not 
statistically significant (P = 0.45 by Student’s t-test). 
B  PARP-1 activity (log10 transformation) in HV men (n = 20), HV women (n = 36), CP men (n 
= 65) and CP women (n = 53). Each data point, a single individual; horizontal line, mean for 
the respective groups of samples. The difference between HV men and women is 
statistically significant (P=0.04 by Student’s t-test). 
 
Fig. 3 A Scatter plot of PARP activity in HV and CP in subjects with T2444C T/T, T/C and 
C/C genotype, respectively. B Scatter plot of PARP-1 expression in HV and CP in subjects 
with promoter polymorphism: SS – short alleles (CA)11-12/(CA)11-12, SL – short/long alleles 
(CA)11-12/(CA)13-20, LL - long/long alleles (CA)13-20/(CA)13-20, respectively.  
 
Fig. 4  
A Correlation between PARP-1 expression (log10 transformation) and PARP activity (log10 
transformation) in HV and B in CP. 
 
Fig. 5  
A Correlation between age and PARP activity (log10 transformation).  
B Correlation between age and PARP-1 expression (log10 transformation).  
 
 
Fig. 6  
A Effect of estrogen (E2) on the PARP activity in the CD1 males, castrated males and 
females mice. Blood from 3 (controls) or 5 (treated) animals in each group was pooled and 
used as a single sample. Values are mean ± SEM. All P values were significant (Student’s t-
test).  
B Effect of estrogen treatment (E2) on the PARP activity in the liver homogenates from 
female mice. PARP activity was measured in triplicates per liver sample. 3 livers per group 
were used.
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